BioCentury
ARTICLE | Cover Story

Building meditope-enabled mAbs

October 31, 2013 7:00 AM UTC

Linker technologies for generating antibody-drug conjugates typically require a labor-intensive process of reengineering the antibody for every application. Researchers at the Beckman Research Institute at City of Hope have published proof-of-concept data on a platform to generate mAb conjugates with other molecules of interest that eliminates the need to reengineer the antibody for each conjugate.1

Institute spinout Meditope Biosciences Inc. is commercializing the technology, which involves building a site into mAbs that can bind to peptides called meditopes that serve as linkers to various payloads. The startup raised $3.6 million in a series A round in July and is seeking industry partnerships...